Related Experiment Videos

Microparticle generation during in vitro platelet activation by anti-CD9 murine monoclonal antibodies

S Nomura1, H Nagata, M Suzuki

  • 1First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.

Thrombosis Research
|June 1, 1991
PubMed

Insights

Two anti-CD9 antibodies were studied for their effects on platelets and microparticle release. MALL13 demonstrated unique platelet interactions and increased microparticle production, suggesting roles in platelet function and coagulation.

Area of Science:

  • Immunology
  • Hematology
  • Cell Biology

Background:

  • Platelets play a crucial role in hemostasis and thrombosis.
  • Microparticles (MPs) are released from activated platelets and contribute to various physiological and pathological processes.
  • CD9 is a cell surface glycoprotein found on platelets, implicated in platelet activation and aggregation.

Purpose of the Study:

  • To investigate the effects of two anti-CD9 murine monoclonal antibodies (NNKY1-19 and MALL13) on platelet function and microparticle release.
  • To characterize the glycoprotein composition and functions of antibody-induced platelet-derived microparticles.
  • To elucidate the distinct mechanisms of action of MALL13 on platelets in different conditions.

Main Methods:

  • Flow cytometry was employed to analyze platelet responses and microparticle formation.
  • Two anti-CD9 monoclonal antibodies, NNKY1-19 and MALL13, were used to stimulate platelets in vitro.
  • Platelet-rich plasma (PRP) and washed platelets (WP) were utilized to assess antibody effects under varying conditions.
  • Electron microscopy was used to examine ultrastructural changes in platelets.
  • Complement components (C1q, C3) binding and fibrinogen binding were measured.

Main Results:

  • NNKY1-19 induced platelet aggregation, consistent with previous findings.
  • MALL13 exhibited distinct effects on platelets in PRP compared to WP, including complement-dependent optical density changes and inhibition by anti-GPIIb/IIIa in WP but not PRP.
  • MALL13 stimulation led to increased lactate dehydrogenase (LDH) release and vacuole formation within platelets in PRP.
  • Both antibodies increased the number of released MPs, which were rich in CD9 protein.
  • MALL13 significantly enhanced C1q and C3 binding to platelets and accelerated MP production in the presence of complement.

Conclusions:

  • MALL13 exerts distinct, dual effects on platelets depending on the presence of plasma components.
  • Anti-CD9 antibodies, particularly MALL13, promote the release of CD9-rich microparticles.
  • MALL13's interaction with platelets, complement, and subsequent MP generation may link platelet function to coagulation regulation.

Related Concept Videos